Effect of high dose per pulse flattening filter-free beams on cancer cell survival
Effect of high dose per pulse flattening filter-free beams on cancer cell survival
复制标题
DOI：
10.1016/j.radonc.2011.05.072
复制
发表时间：
2011-10-01
影响因子：
5.7
通讯作者：
Zaugg, Kathrin
中科院分区：
文献类型：
--
作者：
Lohse, Ines;Lang, Stephanie;Zaugg, Kathrin
目的：研究使用高剂量的每脉冲无滤波（FFF）光束与标准扁平光束相比，在癌细胞存活方面是否存在统计学上的显著差异。材料和方法：为了验证扁平束和FFF束的放射生物学效应，用不同剂量率的5或10 Gy照射两种胶质母细胞瘤细胞系。进行剂量验证并进行菌落形成测定。为了比较我们数据的可预测性，我们将放射生物学模型包括在内。结果：本文的研究结果表明，使用FFF光束照射胶质母细胞瘤细胞系比标准扁平光束更有效地降低了克隆细胞的存活率，并且单次剂量越高，效果越显著。有趣的是，在我们的实验环境中，FFF光束的放射生物学效应取决于每脉冲的剂量，而不是递送时间。所使用的放射生物学模型能够描述在6和24 Gy/min之间观察到的剂量率依赖性。结论：每脉冲剂量可能成为影响肿瘤细胞存活的重要因素。使用高剂量率，迫切需要重新检查目前使用的放射生物学模型以及所涉及的分子机制。2011爱思唯尔爱尔兰有限公司版权所有。放射治疗与肿瘤学101 (2011)226-232
Purpose: To investigate if there is a statistically significant difference in cancer cell survival using a high dose per pulse flattening filter-free (FFF) beam compared to a standard flattened beam.Material and methods: To validate the radiobiological effect of the flattened and FFF beam, two glioblastoma cell lines were treated with either 5 or 10 Gy using different dose rates. Dose verification was performed and colony formation assays were carried out. To compare the predictability of our data, radiobiological models were included.Results: The results presented here demonstrate that irradiation of glioblastoma cell lines using the FFF beam is more efficient in reducing clonogenic cell survival than the standard flattened beam, an effect which becomes more significant the higher the single dose. Interestingly, in our experimental setting, the radiobiological effect of the FFF beam is dependent on dose per pulse rather than on delivery time. The used radiobiological models are able to describe the observed dose rate dependency between 6 and 24 Gy/min.Conclusion: The results presented here show that dose per pulse might become a crucial factor which influences cancer cell survival. Using high dose rates, currently used radiobiological models as well as molecular mechanisms involved urgently need to be re-examined. (C) 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 101 (2011) 226-232